Latest Insider Transactions at Adaptimmune Therapeutics PLC (ADAP)
This section provides a real-time view of insider transactions for Adaptimmune Therapeutics PLC (ADAP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptimmune Therapeutics PLC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptimmune Therapeutics PLC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
Cintia Piccina Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
24,531
-39.05%
|
$0
$0.93 P/Share
|
|
Jan 17
2024
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
18,908
-40.39%
|
$0
$0.67 P/Share
|
|
Jan 17
2024
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
18,114
-40.39%
|
$0
$0.67 P/Share
|
|
Jan 17
2024
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,276
-40.39%
|
$0
$0.67 P/Share
|
|
Jan 17
2024
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,080
-40.15%
|
$0
$0.67 P/Share
|
|
Jan 16
2024
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,681
-39.99%
|
$0
$0.79 P/Share
|
|
Jan 16
2024
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
4,681
-39.99%
|
$0
$0.79 P/Share
|
|
Jan 16
2024
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,287
-40.48%
|
$0
$0.79 P/Share
|
|
Jan 16
2024
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,304
-39.75%
|
$0
$0.79 P/Share
|
|
Jan 12
2024
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
5,220
-39.87%
|
$0
$0.85 P/Share
|
|
Jan 12
2024
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,257
-39.54%
|
$0
$0.85 P/Share
|
|
Jan 12
2024
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,220
-39.87%
|
$0
$0.85 P/Share
|
|
Jan 12
2024
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,799
-39.71%
|
$0
$0.85 P/Share
|
|
Jan 11
2024
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
4,009
-39.64%
|
$0
$0.84 P/Share
|
|
Jan 11
2024
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,945
-39.37%
|
$0
$0.84 P/Share
|
|
Jan 11
2024
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,009
-39.64%
|
$0
$0.84 P/Share
|
|
Jan 11
2024
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,009
-39.64%
|
$0
$0.84 P/Share
|
|
Sep 01
2023
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,403
-41.06%
|
$0
$0.78 P/Share
|
|
Aug 01
2023
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
3,096
-39.62%
|
$0
$0.91 P/Share
|
|
Jul 10
2023
|
Garry E Menzel Director |
SELL
Open market or private sale
|
Direct |
47,702
-38.86%
|
$0
$0.91 P/Share
|
|
Jun 27
2023
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,333
-39.87%
|
$0
$0.92 P/Share
|
|
Jun 01
2023
|
Garry E Menzel Director |
BUY
Grant, award, or other acquisition
|
Direct |
209,931
+50.0%
|
-
|
|
Jun 01
2023
|
Garry E Menzel Director |
BUY
Grant, award, or other acquisition
|
Indirect |
401,293
+50.0%
|
-
|
|
Jan 31
2023
|
Cintia Piccina Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,890
-37.84%
|
$11,890
$1.87 P/Share
|
|
Jan 17
2023
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,057
-42.96%
|
$10,057
$1.86 P/Share
|
|
Jan 17
2023
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,159
-38.21%
|
$2,159
$1.86 P/Share
|
|
Jan 17
2023
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,440
-37.94%
|
$4,440
$1.86 P/Share
|
|
Jan 17
2023
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
4,440
-37.94%
|
$4,440
$1.86 P/Share
|
|
Jan 12
2023
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,763
-42.99%
|
$18,763
$1.71 P/Share
|
|
Jan 12
2023
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,449
-37.93%
|
$7,449
$1.71 P/Share
|
|
Jan 12
2023
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
4,973
-37.98%
|
$4,973
$1.71 P/Share
|
|
Jan 12
2023
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,973
-37.98%
|
$4,973
$1.71 P/Share
|
|
Jan 11
2023
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,042
-42.99%
|
$13,042
$1.75 P/Share
|
|
Jan 11
2023
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,843
-38.0%
|
$3,843
$1.75 P/Share
|
|
Jan 11
2023
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
3,843
-38.0%
|
$3,843
$1.75 P/Share
|
|
Jan 11
2023
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,843
-38.0%
|
$3,843
$1.75 P/Share
|
|
Jan 04
2023
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,073
-43.34%
|
$5,073
$1.69 P/Share
|
|
Jan 04
2023
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
876
-39.16%
|
$876
$1.69 P/Share
|
|
Jan 04
2023
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
1,100
-38.94%
|
$1,100
$1.69 P/Share
|
|
Jan 04
2023
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,584
-38.27%
|
$3,584
$1.69 P/Share
|
|
Sep 01
2022
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,536
-43.34%
|
$2,536
$1.97 P/Share
|
|
Aug 01
2022
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
2,983
-38.18%
|
$2,983
$1.77 P/Share
|
|
Aug 01
2022
|
Cintia Piccina Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
21,040
-37.66%
|
$21,040
$1.77 P/Share
|
|
Jul 05
2022
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
1,973
-38.86%
|
$1,973
$1.68 P/Share
|
|
Jun 27
2022
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,562
-43.78%
|
$2,562
$1.63 P/Share
|
|
May 20
2022
|
Gavin Wood Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
39,000
+28.89%
|
$0
$0.29 P/Share
|
|
Jan 18
2022
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,096
-47.4%
|
$33,288
$3.19 P/Share
|
|
Jan 18
2022
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,121
-37.54%
|
$6,363
$3.19 P/Share
|
|
Jan 18
2022
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
4,368
-37.32%
|
$13,104
$3.19 P/Share
|
|
Jan 18
2022
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,368
-37.32%
|
$13,104
$3.19 P/Share
|